In the BioHarmony Drug Report Database

"Preview" Icon

Enzalutamide

Xtandi (enzalutamide) is a small molecule pharmaceutical. Enzalutamide was first approved as Xtandi on 2012-08-31. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against androgen receptor. Xtandi’s patents are valid until 2027-08-13 (FDA).

 

Trade Name

 

Xtandi
 

Common Name

 

enzalutamide
 

ChEMBL ID

 

CHEMBL1082407
 

Indication

 

prostatic neoplasms
 

Drug Class

 

Non-steroid antiandrogens

Image (chem structure or protein)

Enzalutamide structure rendering